Addressing Unmet Needs in the Management of Small Cell Lung Cancer: Treatment of Brain Metastases, Quality of Life, and the Role of Real-World Evidence Authors: Yunfei Dai, Jing Fei Published: 2026 ABSTRACT Opinion StatementSmall cell lung cancer (SCLC) is a highly aggressive neuroendocrine tumor. Although patient survival has been significantly improved by immune checkpoint inhibitors combined with chemotherapy, three major unmet needs remain in SCLC management. First, while prophylactic cranial irradiation (PCI) can reduce the risk of brain metastases, its neurotoxicity limits its use, particularly in elderly patients or those with neurological deficits. Whole-brain radiotherapy (WBRT) remains the primary approach for brain metastases, and hippocampal-avoidance WBRT (HA-WBRT) combined with neuroprotective agents can significantly reduce cognitive risks. Stereotactic radiosurgery (SRS) has shown survival benefits and less cognitive damage for patients with up to 10 brain metastatic lesions. Emerging therapies, such as antibody-drug conjugates targeting B7-H3/DLL3 (I-Dxd, ZL-1310) and bispecific antibody tarlatamab, have demonstrated intracranial response rates of 62.5%-71%. Regardless of whether the brain metastases had previously undergone radiation therapy, the novel drugs showed consistent activity, indicating promising improvements in the prognosis of brain metastases. Second, the rapid progression and severe treatment-related toxicity of SCLC greatly affect patients’ physical and mental well-being. Therefore, quality of life (QoL) should be prioritised. Strategies to improve QoL include early palliative care, proactive symptom management, application of HA-WBRT or SRS to preserve neurocognitive function, and novel agents such as tarlatamab to alleviate symptoms including cough and dyspnoea. Third, real-world evidence (RWE), which complements clinical trial data by reflecting treatment efficacy and safety in routine clinical practice, is gaining increasing recognition but faces challenges due to data heterogeneity, bias, and lack of methodological standardization. Future directions involve developing new drugs with high blood-brain barrier penetration, such as radioligand therapy, conducting prospective studies to optimize HA and SRS applications, establishing high-quality RWE databases to support personalized treatments, exploring molecular subtypes (SCLC-A/N/P/I) and leveraging AI technologies to advance precision radiotherapy. SCLC management needs to be patient-centered, integrating precise treatment of brain metastases, QoL improvement, and the application of RWE to achieve a balance between survival benefits and QoL.Keywords: Small cell lung cancer, Brain metastases, Quality of life, Real-world evidence Introduction Small cell lung cancer (SCLC), a neuroendocrine tumor closely associated with smoking, is characterized by rapid proliferation, high invasiveness, and high metastatic potential [1]. Approximately 10%−15% of all newly diagnosed lung cancers are SCLC, and approximately 70% of patients are at an advanced (extensive-stage) stage at the time of initial diagnosis [2]. In 2024, the number of newly diagnosed SCLC cases in China was approximately 157,500, and it is expected to increase to 184,000 by 2030 [3, 4]. For more than two decades, platinum-based chemotherapy has been the standard first-line treatment for SCLC. Although SCLC is highly sensitive to chemotherapy, with an initial response rate exceeding 50%, it is prone to recurrence and metastasis. The median overall survival (OS) is only 7–10 months, with the 1-year and 2-year OS rates of 29.4% and 7% respectively [5], indicating a significant disease burden. In recent years, the combination of immune checkpoint (PD-1/L1) inhibitors and chemotherapy has transformed the treatment landscape of SCLC. Large-scale, global, multi-center phase III clinical trials such as IMpower133, CASPIAN, and ADRIATIC have confirmed that immunotherapy can significantly prolong OS in patients with SCLC [6]. However, the treatment of SCLC still faces numerous challenges and unmet medical needs. Firstly, brain metastasis is an important factor affecting the survival and quality of life of patients with SCLC. The median OS of SCLC patients with brain metastases is only 4.9 months, and treatment options remain limited [7]. Secondly, the high malignancy of SCLC and the adverse reactions associated with treatment significantly affect patients’ physical and mental health. However, compared with survival outcomes, the quality of life has received less attention in clinical research or treatment practice [8]. Thirdly, the value of real-world evidence (RWE) in SCLC management is becoming increasingly prominent, with the potential to profoundly influence clinical practice and guideline development [9]. Therefore, we reviewed and discussed the unmet medical needs in current SCLC management from these three aspects. Challenges and Management of Brain Metastases in SCLC Epidemiology and Diagnostic Methods of Brain Metastases in SCLC The incidence of brain metastases at the initial diagnosis of SCLC is approximately 10%−18%, with nearly 30% of patients being asymptomatic. The incidence increases to 60%−80% among patients who survive for more than 2 years [10]. Brain metastases can lead to increased intracranial pressure, resulting in headache, vomiting, and papilloedema, as well as a series of neuropsychiatric symptoms including seizures, cranial nerve dysfunction, and sensorimotor dysfunction [11]. These manifestations substantially impair patients’ quality of life and shorten survival. Therefore, early detection and management of brain metastases are essential for improving the prognosis of patients. Currently, the NCCN guidelines recommend brain imaging for all patients with SCLC at the time of diagnosis. Contrast-enhanced MRI is the preferred imaging modality, with contrast-enhanced CT as an alternative [12]. PET-CT is less sensitive than either contrast-enhanced MRI or CT in detecting brain metastases [13]. Current Treatment Strategies for Brain Metastases in SCLC Prophylactic Cranial Irradiation (PCI) In the chemotherapy era, Aupérin et al. conducted a meta-analysis of individual data from 987 SCLC patients enrolled in 7 randomized clinical trials [14]. All of these patients achieved complete remission after initial treatment, and most of them had limited-stage SCLC (LS-SCLC). The analysis demonstrated that PCI reduced the 3-year cumulative incidence of brain metastases from 58.6% to 33.3% and increased the 3-year OS rate from 15.3% to 20.7% [14]. Based on these findings, PCI has become the standard treatment for patients with LS-SCLC who respond to initial treatment. For extensive-stage SCLC (ES-SCLC), a phase III clinical trial (NCT00016211) by the European Organization for Research and Treatment of Cancer (EORTC) showed that PCI reduced the incidence of symptomatic brain metastases and prolong OS in patients who responded to initial chemotherapy [15]. The 1-year cumulative incidence of symptomatic brain metastases in the PCI group was 14.6%, representing a 25.8% reduction compared with the control group, and the 1-year OS rate increased by 13.8% [15]. However, a Japanese randomized phase III clinical trial challenged the role of PCI [16]. This study enrolled patients with ES-SCLC, all of whom underwent baseline brain MRI examination and were randomly assigned to receive PCI plus MRI monitoring or MRI monitoring alone (every 3 months in the first year and every 6 months in the second year). The results showed that the 1-year cumulative risk of brain metastases in the PCI plus MRI monitoring group was reduced by 27.9%, consistent with the results of the EORTC study. However, no significant difference in OS between the two groups was observed, with median OS of 11.6 months and 13.7 months, respectively (HR 1.27, p = 0.094). The 1-year OS rates in these two groups were 48.4% and 53.6%, respectively. These findings suggest that active MRI monitoring can detect brain metastases at an early stage and enable effective salvage treatment, which can also prolong the survival of patients [16]. Both the EORTC and the Japanese studies have limitations. The EORTC study did not mandate baseline head MRI/CT scans to exclude brain metastases, and some patients with asymptomatic brain metastasis may have been included, leading to an overestimation of the effect of PCI [15]. The Japanese study lacked data on quality of life and neurotoxicity and was terminated early due to an interim futility analysis [16]. Given the existing evidence on the efficacy and safety of PCI, the ASTRO and ESMO guidelines emphasize a multidisciplinary, shared decision-making approach for whether ES-SCLC patients should receive PCI. Other phase III clinical trials comparing PCI plus active MRI monitoring with active MRI monitoring alone, such as EORTC PRIMALung (NCT04790253) and SWOG MAVERICK (NCT04155034), are ongoing. In recent years, with immunotherapy playing an increasingly important role in the treatment of SCLC, the role of PCI in this context warrants further evaluation. In the ADRIATIC study [17], 54% of LS-SCLC patients received PCI after concurrent chemoradiotherapy and before consolidation therapy with durvalumab. The subgroup analysis showed that, compared with placebo, durvalumab consolidation therapy yielded improved efficacy regardless of whether patients had received PCI. However, in the overall study population, patients who received PCI had higher 3-year OS and PFS rates than those who did not (62.1% vs. 50.2% and 54.6% vs. 37.1% respectively) [17]. In clinical trials enrolling patients with ES-SCLC who received immunotherapy, the role of PCI remains controversial. The proportion of patients received PCI was 11% in IMpower133, 13% in KEYNOTE-604, 1% in CAPSTONE-1, not allowed in CASPIAN, and relevant data in ASTRUM-005 and ETER-701 studies were not reported [18]. The ongoing MAVERICK trial (NCT04155034), which stratifies patients based on PCI receipt, will provide further clarification on the role of PCI in the context of ES-SCLC immunotherapy. While the potential clinical benefits of PCI have been demonstrated in many clinical trials, its toxicities remain a significant concern. Short-term adverse reactions of PCI include fatigue, hair loss and delayed hair growth, scalp erythema, and increased intracranial pressure, among others. Some of these can be prevented by low-dose corticosteroids. Long-term adverse reactions include ventricular dilation, brain atrophy, and periventricular and subcortical white matter changes. Some patients may experience intellectual disability, cognitive impairment and ataxia, while dementia symptoms are relatively rare [19]. Currently, the ASTRO guidelines do not recommend PCI for patients with neurocognitive dysfunction, and the ESMO guidelines do not recommend PCI for patients over 75 years old or with an ECOG PS score over 2. For these patients, active MRI monitoring may be a preferable option [20, 21]. Whole-Brain Radiotherapy (WBRT) WBRT is the preferred local treatment for brain metastases in SCLC, largely due to the high incidence of multiple metastases in this population. Even in patients who have previously received PCI, WBRT can still be an option for multiple brain metastases. For patients with an expected survival exceeding 4 months, sequential stereotactic radiotherapy (SRT) following WBRT, or intensity-modulated radiotherapy with simultaneous integrated boost, can be considered to achieve better efficacy [22]. With the prolonged survival of SCLC patients with brain metastases, the adverse effects of WBRT, particularly neurocognitive dysfunction, have gained increasing attention [23]. The application of hippocampal avoidance (HA) may reduce the neurocognitive toxicity associated with WBRT. When the radiation dose to the hippocampal area is limited to 9–16 Gy, the incidence of neurocognitive dysfunction can be significantly reduced without increasing the risk of metastasis in the hippocampal area [24]. The NRG CC001 study explored whether combining HA with memantine, a neurocognitive protective agent, could further reduce neurocognitive toxicity. The results showed that although OS was not prolonged, the risk of cognitive impairment was reduced by 26% (P = 0.02) [25]. Stereotactic Radiosurgery (SRS) SRS is defined as a high dose of radiation delivered in 1 to 5 fractions. It has advantages of accurate positioning, concentrated radiation delivery to the tumor lesion, and less damage to the surrounding normal tissues. SRS can effectively control the progression of intracranial lesions, alleviate neurological symptoms, and protect neurocognitive function. Therefore, it has become an important treatment option for SCLC brain metastases. Generally, SRS is considered a salvage treatment for new or progressive brain metastases after a previous PCI or WBRT [26]. However, recent findings suggest that SRS can also be used for selected patients with newly diagnosed brain metastases of small volume and limited number who have not undergone PCI, as it is associated with a lower risk of neurocognitive damage compared with WBRT. A large-scale, single-arm, multicenter and retrospective cohort study included 710 SCLC patients with brain metastases (median number of brain metastases of 2.5) who received SRS as the initial radiotherapy [27]. Investigators also acquired individual patient data from a large, published data set of first line WBRT for SCLC to compare SRS outcomes with contemporary WBRT outcomes. After propensity score matching, the SRS cohort exhibited a shorter time to central nervous system (CNS) progression but a significantly longer OS (6.5 vs. 5.2 months; P = 0.003) compared with the WBRT cohort. While limitations such as the retrospective nature of the study and variations in systemic treatment preclude a definitive conclusion that SRS is superior, these data provide a benchmark for SRS outcomes and support its use as a first-line treatment option in carefully selected patients with SCLC [27]. Another meta-analysis included 7 retrospective studies showed that SRS and WBRT had comparable effects on OS in SCLC patients with brain metastases [28]. The randomized phase II ENCEPHALON trial evaluated the impact of SRS or WBRT on neurocognitive function in SCLC patients who had not previously received brain radiotherapy and had no more than 10 brain metastases. The results showed that the proportion of patients with a decline in the HVLT-R total recall score was significantly lower in the SRS group than in the WBRT group (7.7% vs. 24.0%), and there was no significant difference in OS between the two groups [29]. Recently, a single-arm phase II clinical trial evaluated 100 SCLC patients with no more than 10 brain metastases who received SRS as the initial radiotherapy [30]. The median OS was 10.2 months, and the 1-year neurologic death rate (neurologic death defined as marked, progressive radiographic progression in the brain accompanied by corresponding neurologic symptomatology in the absence of systemic disease progression or systemic symptoms of a life-threatening nature) was 11.0% (95% CI, 5.8% to 18.1%), which was not significantly higher than the historical rate of 17.5% in patients managed with WBRT [30]. Overall, SRS may better preserve cognitive function and quality of life without compromising the OS. Large-scale prospective randomized phase III clinical trials, such as NRG CC009 and SHARP (NCT06457906), are underway and are expected to further clarify the roles of SRS in the treatment of SCLC brain metastases. Challenges of Penetrating the Blood-Brain Barrier and Emerging Therapies In the chemotherapy era, it was generally believed that the blood-brain barrier limited the efficacy of chemotherapy on brain metastases in SCLC. In the era of immunotherapy, the benefits for SCLC patients with brain metastases remain limited. The proportion of patients with brain metastases included in large-scale phase III clinical trials has been relatively small, and data on intracranial efficacy are lacking. Table 1 presents the OS data of SCLC patients with brain metastases from phase III clinical trials. Table 1OS data of SCLC patients with brain metastases in phase III clinical trials of immune checkpoint inhibitorsClinical trialNumber of pts with BM (%)Median OS, monthsOS HR (95% CI)IMpower13335 (9)8.5 vs. 9.70.96 (0.46–2.01) [31]CASPIAN55 (10)11.7 vs. 8.80.79 (0.44–1.41) [32]ASTRUM-00578 (13)13.9 vs. 10.00.61 (0.33–1.13) [33]ETER70151 (10)NR0.64 (0.29–1.41) [34]CAPSTONE-110 (2)NRNR [35]EXTENTORCH7 (2)NRNR [36]RATIONALE-3125 (1)NRNR [37]BM brain metastases, pts patients OS data of SCLC patients with brain metastases in phase III clinical trials of immune checkpoint inhibitors BM brain metastases, pts patients In recent years, drugs with innovative mechanisms have shown improved ability to cross the blood-brain barrier in SCLC patients with brain metastases in early-phase clinical studies. Data from the phase I/II study (NCT04471727) presented at the 2024 WCLC showed that MK-6070, a trispecific T-cell engager targeting DLL3, CD3, and albumin, exhibited positive antitumor activity in SCLC patients with baseline brain metastases after at least two prior lines of therapy. The ORR was 36%, and the extracranial ORR was 50%, both higher than those in the non-brain metastasis group (ORR of 18% in the non-brain metastasis group) [38]. Ifinatamab deruxtecan (I-DXd) is an antibody-drug conjugate (ADC) targeting the B7-H3 molecule, which is highly expressed in SCLC. In the phase II IDeate-Lung01 trial (NCT05280470), both the systemic and intracranial ORR of I-DXd in relapsed SCLC patients with baseline brain metastases reached 46.2%, indicating strong intracranial antitumor activity [39]. At the 2025 ASCO Annual Meeting, a phase I clinical trial reported the results of a novel agent targeting DLL3, ADC ZL-1310. The results showed that among 89 relapsed SCLC patients who received ADC ZL-1310 (30% of whom had baseline brain metastases), the confirmed systemic ORR of patients with brain metastases was 46%. In patients who had not received brain radiotherapy, the confirmed ORR was 71% [40]. Tarlatamab is a bispecific T-cell engager that simultaneously binds to DLL3 and CD3 on the surface of T cells, inducing an immune killing effect of T cells on SCLC cells. In the phase I/II DeLLphi-300 trial, the intracranial ORR of tarlatamab was 62.5%, with a median duration of intracranial response of 7.4 months [41]. In the recently reported phase III DeLLphi-304 trial, tarlatamab as a second-line therapy significantly prolonged OS relapsed SCLC (HR 0.60, 95% CI 0.47–0.77; P < 0.001), especially in patients with baseline brain metastases (HR 0.45, 95% CI 0.31–0.65) [42]. Further data on the intracranial efficacy of tarlatamab are eagerly awaited. It is worth noting that all the trials mentioned above included patients with asymptomatic brain metastases, regardless of whether they had received treatment including radiotherapy. Nevertheless, the novel drugs achieved similar or better efficacy in untreated patients with brain metastases compared to those who had previously received radiotherapy, demonstrating excellent intracranial activity (Table 2) [38–41]. Table 2ORR data for SCLC patients with brain metastases in clinical trials of novel drugsClinical trialsDrugsNumber of pts with BM (%)ORR for pts w/o prior radiationORR for pts w/prior radiationNCT04471727MK-607028 (56)Overall 36%*IDeate-Lung01 (NCT05280470)Ifinatamab deruxtecan (I-DXd)65 (47)57.7%**38.5%**NCT06179069ZL-131027 (30)71%33%DeLLphi-300 (NCT03319940)Tarlatamab28 (25)NR62.5%****96% (27/28) of pts with BM had received prior brain radiation**Intracranial confirmed ORR per RECIST 1.1***Intracranial ORR per mRANO-BMBM brain metastases, pts patients, w/o without, w/ with ORR data for SCLC patients with brain metastases in clinical trials of novel drugs *96% (27/28) of pts with BM had received prior brain radiation **Intracranial confirmed ORR per RECIST 1.1 ***Intracranial ORR per mRANO-BM BM brain metastases, pts patients, w/o without, w/ with Radioligand therapy (RLT), also known as targeted radioligand therapy, uses ligands labelled with radionuclides (such as Lu-177 or Y-90) to bind to specific receptors on the surface of tumor cells, thereby precisely delivering radiation to tumor to achieve therapeutic effects while minimizing damage to surrounding normal tissues. RLT has made significant progress in the treatment of prostate cancer. The radioligand 177Lu-PSMA-617, which targets prostate-specific membrane antigen (PSMA) can significantly prolong the survival of patients with metastatic castration-resistant prostate cancer and has been approved for marketing [43]. Recent research found that brain tumor lesions can uptake the radioligand targeting PSMA. This non-randomized prospective imaging study included ten patients (n = 5 high-grade glioma, n = 4 lung cancer brain metastasis and n = 1 breast cancer brain metastasis) received 1.5 MBq/kg [68Ga]Ga-PSMA-11 intravenously and super-selective intra-arterial (ssIA)-administration. The result shown that ssIA-administration is safe and leads to a median 15-fold higher radioligand uptake at the tumor site, therewith qualifying more patients for treatment and enhancing the potential of therapy [44]. MP0712, a novel DLL3-targeting 212Pb-based radio-DARPin therapeutic agent, demonstrated promising tumor shrinkage and stabilization effects in mouse xenograft model of SCLC [45]. These preclinical findings support a study of [212Pb]Pb-MP0712 in patients with SCLC and other DLL3 expressing solid tumors is ongoing (NCT07278479). Quality of Life in SCLC Patients Importance of Quality of Life The aggressiveness of SCLC and its treatments significantly affect patients’ physical, psychological, and social functions. For SCLC patients, quality of life is as important as survival, especially in patients with extensive-stage disease. Patients with SCLC often suffer from various symptoms and treatment-related adverse events, which seriously affect their physical and mental health. Therefore, in the treatment of SCLC, in addition to pursuing survival benefits, it is very important to improve the quality of life throughout disease management [46]. Main Symptoms Affecting Quality of Life The quality of life of patients with SCLC is significantly affected by various symptoms and treatment-related adverse events. Common symptoms include: (1) Pulmonary symptoms, such as dyspnoea, cough, and hemoptysis, are among the most frequent in SCLC patients and can severely affect patients’ comfort and ability to perform daily activities. (2) Neurological symptoms. Up to 80% of SCLC patients may develop brain metastases, with 15% presenting at the time of initial diagnosis [3]. Brain metastases can lead to a series of neurological symptoms, which seriously affect patients’ daily living abilities and independence. Treatment-related adverse events include: (1) Chemotherapy- and radiotherapy-induced adverse events. Conventional chemotherapy and radiotherapy may cause side effects such as fatigue, nausea, vomiting, hair loss, loss of appetite, and weight loss [47, 48]. Although WBRT can effectively control brain metastases, it may lead to neurocognitive side effects such as decline in executive function, learning, and memory. PCI may also cause short-term side effects (e.g., headache, fatigue, hair loss, nausea, vomiting) and long-term decline in neurocognitive function (e.g., memory loss, impaired concentration, and unsteady gait), especially in elderly patients [49]. (2) Chemoimmunotherapy-induced adverse events. The standard first-line treatment for ES-SCLC is platinum-based chemotherapy combined with immune checkpoint inhibitors (such as the PD-L1 inhibitors durvalumab or atezolizumab) [12]. In addition to the common chemotherapy-induced adverse events (e.g., fatigue, nausea, vomiting, bone marrow suppression, peripheral neuropathy), this combination treatment also introduces immune-related adverse events (irAEs) [50]. irAEs can affect multiple organ systems, including the lungs (pneumonia), intestines (colitis), liver (hepatitis), endocrine glands (thyroid dysfunction), and kidneys (kidney injury) [50]. Although most irAEs are mild to moderate, severe or even life-threatening events may occur [50]. (3) New therapies-induced adverse events. Although new therapies bring survival benefits, they can also induce unique side effects. For example, the bispecific T-cell engager tarlatamab may cause cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) [51]. These adverse events usually occur during the first treatment cycle [51, 52], and the incidence and severity of ICANS may be higher in patients with untreated brain metastases [51]. Quality of Life Assessment Tools To comprehensively assess the quality of life of SCLC patients, patient-reported outcomes (PROs) and corresponding standardized questionnaires are often used in clinical practice and research. The standardized questionnaires included: (1) European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30). This widely used core questionnaire contains 30 items that assess five functional domains (physical, role, emotional, cognitive, and social functions), three symptom domains (fatigue, nausea and vomiting, and pain), one global health status domain, and six single items (such as dyspnoea, insomnia, loss of appetite, constipation) [53]. (2) EORTC QLQ-BN20. This is a brain cancer module of EORTC QLQ-C30, containing 20 items, designed to assess specific symptoms and functional impairments in patients with brain tumors, such as future uncertainty, visual disorders, motor dysfunction, communication deficit, headache, seizures, lethargy, hair loss, leg weakness, and bladder control. Scale scores are calculated by linearly converting the original scores to a range of 0–100 points, where a score of 100 represents the best global health status, the best functional state, or the worst symptoms [54]. (3) Other PROs. PROs directly reflect patients’ perception of their own symptoms and treatment experiences, which are crucial for assessing the real-world impact of treatment. For example, in the DeLLphi-304 study, tarlatamab not only significantly improved the OS and PFS of patients with ES-SCLC but also significantly alleviated common symptoms such as dyspnoea and cough as reported by patients, thereby improving their quality of life [52]. Strategies to Improve Quality of Life Improving the quality of life of patients with SCLC requires a comprehensive and multifaceted strategy: (1) Symptom management. Proactively address symptoms, such as controlling pain with painkillers, using anti-emetics to relieve nausea and vomiting, and taking appropriate measures to manage fatigue [55]. (2) Supportive and palliative care. Early introduction of supportive and palliative care can significantly improve symptom control, mental health, and overall quality of life in patients with SCLC, and may even extend survival [56]. (3) Radiotherapy for patients with brain metastases. Multiple studies have shown that SRS is associated with sustained quality of life benefits after treatment. For example, a systematic review of 18 studies showed that the scores from overall quality of life questionnaires (including EORTC QLQ-C30, EQ-5D) and the brain cancer specific questionnaires (including FACT-Br, QLQ-BN20) remained stable before and after SRS, and 19–60% of patients reported improvement or stability in their quality of life at the individual level [57]. Hippocampal sparing is an emerging strategy designed to limit radiation exposure to the hippocampal region, which is responsible for memory and learning, thereby reducing the neurocognitive damage caused by PCI or WBRT [58]. Studies have shown that compared with conventional WBRT or PCI, patients using the hippocampal sparing strategy have a significantly higher probability of cognitive function preservation and recovery [59]. Role of Real-World Evidence (RWE) in SCLC Management Necessity of Real-World Evidence Randomized controlled trials (RCTs) are the “gold standard” for evaluating the efficacy and safety of new therapies [60]. However, their strict inclusion criteria limit generalizability, and study populations may not fully represent the diverse patient groups in clinical practice, which creates a gap between trial results and real-world applicability [61]. For example, patients with SCLC often have brain metastases or poor performance status, and these patients are often excluded from RCTs. Therefore, the value of real-world evidence (RWE) is becoming increasingly prominent. By analyzing data from routine clinical practice (such as electronic health records, registries, insurance claim databases), RWE can complement the limitations of RCTs and provide evidence on the efficacy and safety of treatments in broader patient populations [62]. Such evidence is crucial for understanding the effectiveness of new therapies across different patient subgroups, especially in diseases characterized by complex prognoses and diverse clinical characteristics [63]. Examples of RWE Application in SCLC In recent years, RWE has played an increasingly important role in SCLC treatment. A real-world study evaluated the safety of tarlatamab, a bispecific T-cell engager, in patients with SCLC. The study found that, compared with clinical trials, tarlatamab was associated with a higher incidence of serious adverse events, such as CRS and ICANS, particularly in patients with untreated brain metastases. These findings suggest that, in real-world applications, closer monitoring and management are needed for specific high-risk patient populations [52]. Since the proportion of patients with brain metastases included in phase III clinical trials (such as IMpower133) is lower than that observed in real-world clinical practice, several real-world studies have been conducted to evaluate the effectiveness of first-line immunotherapy combined with chemotherapy in this population. A study by Namgung Y et al. showed that compared with platinum-based chemotherapy alone, patients who received combination of atezolizumab and chemotherapy had a lower incidence of intracranial progression or new intracranial lesions, with significantly improved median intracranial PFS and 12-month intracranial PFS rate (11.7 months vs. 8.2 months, P = 0.003; 48.6% vs. 30.2%, P = 0.001) [64]. Another Chinese real-world study showed that regardless of whether patients received brain radiotherapy, the PFS was longer in patients who received atezolizumab combined with chemotherapy compared with those who received platinum-based chemotherapy alone [65]. As immunotherapy combined with platinum-based chemotherapy has become the standard first-line treatment for ES-SCLC, investigators have begun to focus on the long-term survival data of this regimen in the real world. Several real-world studies have been conducted to evaluate the actual survival benefits of immunotherapy in a broader patient population and provide references for subsequent treatment strategies [66–68]. Challenges in Collecting and Interpreting RWE Although RWE is of great value, there are many challenges in data collection and interpretation [69, 70]. (1) Diversity and heterogeneity of data sources. RWE data may come from various sources, such as electronic health records, patient registries, insurance claim databases, and biobanks. The heterogeneity of these data sources can result in inconsistent data formats and incomplete information, which makes data integration and analysis difficult [71]. (2) Data quality and bias. Unlike the strict inclusion criteria of RCTs, RWE data are collected in daily clinical practice and may suffer from issues such as missing data, non-standard records, or inconsistent measurement methods, which affect data quality. In addition, non-randomized designs may introduce selection bias, confounding, and other biases, making causal inference challenging [72]. (3) Methodological challenges. The lack of standardized methodologies for RWE makes it difficult to compare and integrate findings across studies [73]. Effectively handling confounding factors, selecting appropriate statistical models, and conducting sensitivity analysis are all important methodological obstacles that RWE research needs to overcome. Impact of RWE on Clinical Practice and Guideline Development Despite challenges, RWE in SCLC management is growing increasingly prominent, significantly impacting clinical practice and guideline development [74, 75]. (1) Guiding treatment decisions. RWE provides insights into the performance of treatment regimens in real-world clinical practice, thereby helping clinicians select appropriate treatment options for a broader patient population in clinical practice. This makes treatment decisions more personalized and precise [76]. (2) Identifying unmet needs. By analyzing real-world data, patient subgroups that have not been adequately studied in clinical trials or have poor treatment outcomes can be identified, thereby revealing unmet clinical needs in SCLC management. This helps guide future research directions and new drug development [77]. (3) Driving clinical trial design. Findings from RWE can inform the design of future RCTs, by optimizing the inclusion criteria of clinical trials to make them more relevant to real-world patient populations, or by adjusting trial endpoints to better reflect patient-relevant outcomes in the real world, such as quality of life and symptom control [78]. Conclusion and Future Prospects As a highly aggressive malignant tumor, SCLC poses a severe challenge in clinical management. The management of SCLC should extend beyond tumor control and survival extension and shift towards a patient-centered comprehensive care model. This means that close collaboration among multidisciplinary teams is required, with effective management of brain metastases, continuous improvement of patients’ quality of life, and integration of RWE as the core considerations in treatment decisions. Previous studies have made useful explorations in this regard, such as the role of SRS and HA in improving the quality of life of patients with brain metastases and reducing the risk of cognitive impairment [57, 79], and the supplementation of RWE to address the lack of efficacy data due to the small number of patients with brain metastases included in RCTs [59, 64]. This comprehensive management model aims to maximize patients’ survival benefits while minimizing the burden caused by the disease and treatment, thereby comprehensively improving patients’ benefits. To further optimize the treatment outcomes and quality of life of patients with SCLC, future research should focus on the following key directions. Precise Management and New Therapies for Brain Metastases A deeper understanding of the molecular mechanisms of SCLC brain metastases, including how tumor cells cross the blood-brain barrier, colonize and grow in the brain microenvironment, is needed to develop new therapeutic targets and intervention strategies. Since conventional chemotherapy drugs have difficulty penetrating the blood-brain barrier, future efforts should focus on developing systemic therapies with effective CNS penetration. Optimization of Radiotherapy Strategies In the era of immunotherapy, techniques such as HA-WBRT and HA-PCI should be further optimized. Large-scale phase III clinical trials are needed to define the roles of WBRT and SRS, identify suitable populations, and achieve effective intracranial control while maximizing the preservation of neurocognitive function. Comprehensive Assessment and Improvement of Quality of Life The application of standardized assessment tools should be promoted, and the use and integration of PROs tools, such as EORTC QLQ-C30 and QLQ-BN20, should be encouraged in all SCLC clinical trials and daily practice to more comprehensively and objectively capture patients’ symptom burden and changes in quality of life. Optimization of Symptom Management and Supportive Nursing The management strategies for SCLC-related symptoms (such as dyspnoea, cough, fatigue, and neurological symptoms) should be improved, and early and whole-course intervention of supportive nursing and palliative care should be emphasized to alleviate patient suffering and enhance physical and mental well-being. Impact of New Therapies on Quality of Life Conduct an in-depth assessment of the actual improvement effects of new therapies (such as tarlatamab) on patients’ quality of life and specific symptoms (such as dyspnoea and cough) while prolonging their survival. Deepening and Transformation of RWE Establish and maintain a high-quality real-world database for SCLC, integrating data from diverse sources such as electronic health records and registries to address challenges of data heterogeneity and bias. Promote the application of RWE in clinical decision-making, develop more mature methodologies, and use RWE to complement the limitations of RCTs by providing more instructive treatment options for SCLC patients with complex comorbidities or specific characteristics. Encourage the conduct of real-world studies that include more representative patient populations to ensure findings on new therapies are clinically applicable, thus bridging the gap between research and practice. Integration of New Technologies and Personalized Medicine Explore the potential of AI in precise delineation of the hippocampus, dose prediction and optimization to improve the efficiency and consistency of HA-WBRT and enable personalized radiotherapy based on individual patient’s risk of cognitive dysfunction. Explore precision treatment guided by molecular subtyping to further elucidate the association between the molecular heterogeneity of SCLC subtypes (such as SCLC-A, -N, -P, -I) and treatment sensitivity [80]. For example, the better response of the SCLC-I subtype to chemo-immunotherapy [81] suggests that in the future, the use of immune checkpoint inhibitors can be guided by molecular subtyping, and alternative treatment strategies can be explored for immune “cold” subtype tumors. This strategy is currently being prospectively evaluated in the SWOG S2409 (PRISM) study, which is designed to investigate how these molecular subtypes influence responses to chemo-immunotherapy and biomarker-guided maintenance therapy combinations [82]. Through these multi-dimensional efforts, the treatment landscape of SCLC is expected to be further transformed, ultimately delivering the most effective and patient-centered integrated treatment approach for each patient, thereby prolonging survival and significantly improving quality of life. Key References Kim SY, Park HS, Chiang AC. Small Cell Lung Cancer: A Review. Jama. 2025;333(21):1906-17.○ This reference is of outstanding importance because that it synthesizes recent evidence from the past five years on the molecular biology, treatment strategies, and survival outcomes of small cell lung cancer, offering a "one-stop" update for clinical practice. Kim SY, Park HS, Chiang AC. Small Cell Lung Cancer: A Review. Jama. 2025;333(21):1906-17.○ This reference is of outstanding importance because that it synthesizes recent evidence from the past five years on the molecular biology, treatment strategies, and survival outcomes of small cell lung cancer, offering a "one-stop" update for clinical practice. ○ This reference is of outstanding importance because that it synthesizes recent evidence from the past five years on the molecular biology, treatment strategies, and survival outcomes of small cell lung cancer, offering a "one-stop" update for clinical practice. ○ This reference is of outstanding importance because that it synthesizes recent evidence from the past five years on the molecular biology, treatment strategies, and survival outcomes of small cell lung cancer, offering a "one-stop" update for clinical practice. Aizer AA, Tanguturi SK, Shi DD, Catalano PJ, Shin KY, Ricca I, et al. Stereotactic Radiosurgery in Patients With Small Cell Lung Cancer and 1–10 Brain Metastases: A Multi-Institutional, Phase II, Prospective Clinical Trial. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2025;43(27):2986-97.○ This reference is of outstanding importance because this study evaluated the efficacy and safety of stereotactic radiosurgery (SRS) alone in patients with a limited number (1–10) of small cell lung cancer (SCLC) brain metastases. It explores treatment strategies related to SRS for SCLC brain metastases, challenges the traditional notion that whole-brain radiotherapy (WBRT) is mandatory for SCLC brain metastases, and demonstrates the dual advantages of SRS in achieving local tumor control and preserving cognitive function. Aizer AA, Tanguturi SK, Shi DD, Catalano PJ, Shin KY, Ricca I, et al. Stereotactic Radiosurgery in Patients With Small Cell Lung Cancer and 1–10 Brain Metastases: A Multi-Institutional, Phase II, Prospective Clinical Trial. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2025;43(27):2986-97.○ This reference is of outstanding importance because this study evaluated the efficacy and safety of stereotactic radiosurgery (SRS) alone in patients with a limited number (1–10) of small cell lung cancer (SCLC) brain metastases. It explores treatment strategies related to SRS for SCLC brain metastases, challenges the traditional notion that whole-brain radiotherapy (WBRT) is mandatory for SCLC brain metastases, and demonstrates the dual advantages of SRS in achieving local tumor control and preserving cognitive function. ○ This reference is of outstanding importance because this study evaluated the efficacy and safety of stereotactic radiosurgery (SRS) alone in patients with a limited number (1–10) of small cell lung cancer (SCLC) brain metastases. It explores treatment strategies related to SRS for SCLC brain metastases, challenges the traditional notion that whole-brain radiotherapy (WBRT) is mandatory for SCLC brain metastases, and demonstrates the dual advantages of SRS in achieving local tumor control and preserving cognitive function. ○ This reference is of outstanding importance because this study evaluated the efficacy and safety of stereotactic radiosurgery (SRS) alone in patients with a limited number (1–10) of small cell lung cancer (SCLC) brain metastases. It explores treatment strategies related to SRS for SCLC brain metastases, challenges the traditional notion that whole-brain radiotherapy (WBRT) is mandatory for SCLC brain metastases, and demonstrates the dual advantages of SRS in achieving local tumor control and preserving cognitive function. Damiano P, Stefani A, Avancini A, Belluomini L, Bria E, Pilotto S. Real-world evidence in extensive disease small cell lung cancer: The missing piece of the puzzle. Critical reviews in oncology/hematology. 2025;207:104618.○ This reference is of outstanding importance because this stud demonstrates the indispensable and critical role of Real-World Evidence (RWE) in supplementing the limitations of traditional randomized controlled trials (RCTs), depicting the comprehensive landscape of real-world clinical practice, and guiding individualized treatment and health policy formulation within the context of clinical research and therapeutic decision-making for extensive-stage small cell lung cancer (ED-SCLC). Damiano P, Stefani A, Avancini A, Belluomini L, Bria E, Pilotto S. Real-world evidence in extensive disease small cell lung cancer: The missing piece of the puzzle. Critical reviews in oncology/hematology. 2025;207:104618.○ This reference is of outstanding importance because this stud demonstrates the indispensable and critical role of Real-World Evidence (RWE) in supplementing the limitations of traditional randomized controlled trials (RCTs), depicting the comprehensive landscape of real-world clinical practice, and guiding individualized treatment and health policy formulation within the context of clinical research and therapeutic decision-making for extensive-stage small cell lung cancer (ED-SCLC). ○ This reference is of outstanding importance because this stud demonstrates the indispensable and critical role of Real-World Evidence (RWE) in supplementing the limitations of traditional randomized controlled trials (RCTs), depicting the comprehensive landscape of real-world clinical practice, and guiding individualized treatment and health policy formulation within the context of clinical research and therapeutic decision-making for extensive-stage small cell lung cancer (ED-SCLC). ○ This reference is of outstanding importance because this stud demonstrates the indispensable and critical role of Real-World Evidence (RWE) in supplementing the limitations of traditional randomized controlled trials (RCTs), depicting the comprehensive landscape of real-world clinical practice, and guiding individualized treatment and health policy formulation within the context of clinical research and therapeutic decision-making for extensive-stage small cell lung cancer (ED-SCLC). Author Contributions The literature retrieval, framework design and first draft of the manuscript were completed by Yunfei Dai, and Jing Fei revised and finalized the manuscript and provided the funding support. Funding This work was funded by the Guiding Plan of Xinjiang Production, Construction Corps(No. 2024ZD062). Data Availability No datasets were generated or analysed during the current study. Declarations Ethical Approval Not applicable. Human and Animal Rights and Informed Consent This article does not contain any studies with human or animal subjects performed by any of the authors. Competing interests The authors declare no competing interests. Footnotes Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. References Associated Data Data Availability Statement No datasets were generated or analysed during the current study.